Obama Precision Medicine Plan Would Create Huge U.S. Genetic Biobank
By Jocelyn Kaiser,
Science Insider
| 01. 29. 2015
Untitled Document
The precision medicine initiative proposed by President Barack Obama last week would center on a huge new biobank containing medical records and genetic information for perhaps a million Americans. It would not be created from scratch by enrolling new volunteers, however, but would instead pull together existing studies into one giant database.
That’s according to several scientists familiar with the broad outlines of the project who spoke on background with ScienceInsider. The biobank would be used for studies ranging from finding new disease-gene associations to working out how to use genomic and other molecular information in routine medical care. On Friday, the White House is expected to reveal details of the initiative, which will reportedly cost hundreds of millions of dollars.
Such a national biobank would put the United States in line with other countries, such as the United Kingdom, Iceland, and Japan, which have built large population databases for research and medical care. A similar U.S. biobank has long been on the wish list of National Institutes of Health (NIH) Director Francis Collins, who...
Related Articles
By Emily Baumgaertner Nunn, The New York Times | 09.08.2026
It is one of biology’s most ingenious rhythms: Every baby is born young. No matter how much wear and tear their parents’ DNA accumulated over their lifetimes, reproduction erases the molecular scars, handing a clean slate to the next generation...
What We Inherit by Sam Trejo and Daphne O. Martschenko; and Original Sin by Kathryn Paige Harden have a great deal in common, with substantial differences in style and emphasis. Both books attempt, in different ways, to show the reader just where current research into human genomics stands, where that might be going, and why the authors are interested. In short, the influence of genomic research on our societies is already large and seems likely to change them in ways...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
By Jessica Hamzelou, MIT Technology Review | 07.23.2026
When it comes to organ donation, time is everything. As soon as an organ has been carefully removed from a donor’s body, it starts to deteriorate. Surgeons have a matter of hours to get it into a recipient. Leave...